Peter Sallstig

1.0k total citations
16 papers, 773 citations indexed

About

Peter Sallstig is a scholar working on Rheumatology, Nephrology and Pharmacology. According to data from OpenAlex, Peter Sallstig has authored 16 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 7 papers in Nephrology and 5 papers in Pharmacology. Recurrent topics in Peter Sallstig's work include Gout, Hyperuricemia, Uric Acid (7 papers), Urticaria and Related Conditions (6 papers) and Inflammatory mediators and NSAID effects (5 papers). Peter Sallstig is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (7 papers), Urticaria and Related Conditions (6 papers) and Inflammatory mediators and NSAID effects (5 papers). Peter Sallstig collaborates with scholars based in Switzerland, United States and Türkiye. Peter Sallstig's co-authors include Udayasankar Arulmani, Naomi Schlesinger, Marc De Meulemeester, Dominik Richard, Alexander So, A. Pikhlak, V. Murphy, Eftal Yücel, Andreas Weichselberger and Lawrence J. Singerman and has published in prestigious journals such as Gastroenterology, Journal of Allergy and Clinical Immunology and Ophthalmology.

In The Last Decade

Peter Sallstig

16 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Sallstig Switzerland	8	380	313	252	241	178	16	773
Konstantinos Giannakakis Italy	11	230 0.6×	155 0.5×	75 0.3×	47 0.2×	5 0.0×	28	459
Shinya Ikoma Japan	13	54 0.1×	232 0.7×	205 0.8×	48 0.2×	9 0.1×	23	500
Tianjun Guan China	10	171 0.5×	87 0.3×	65 0.3×	37 0.2×	17 0.1×	33	367
Mianjing Zhou China	12	155 0.4×	370 1.2×	223 0.9×	71 0.3×	4 0.0×	17	794
Hideaki Kaneshige Japan	10	149 0.4×	64 0.2×	49 0.2×	43 0.2×	5 0.0×	36	382
Anqun Chen China	12	211 0.6×	155 0.5×	46 0.2×	29 0.1×	12 0.1×	25	417
Guolan Xing China	14	394 1.0×	161 0.5×	54 0.2×	71 0.3×	4 0.0×	32	706
E. Schrama Netherlands	9	156 0.4×	103 0.3×	29 0.1×	87 0.4×	9 0.1×	17	442
Yutaka Furumitsu Japan	11	43 0.1×	124 0.4×	296 1.2×	41 0.2×	4 0.0×	18	596
Bihua Xu China	11	159 0.4×	237 0.8×	113 0.4×	52 0.2×	3 0.0×	14	588

Countries citing papers authored by Peter Sallstig

Since Specialization

Citations

This map shows the geographic impact of Peter Sallstig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Sallstig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Sallstig more than expected).

Fields of papers citing papers by Peter Sallstig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Sallstig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Sallstig. The network helps show where Peter Sallstig may publish in the future.

Co-authorship network of co-authors of Peter Sallstig

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Sallstig. A scholar is included among the top collaborators of Peter Sallstig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Sallstig. Peter Sallstig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Dugel, Pravin U., Glenn J. Jaffe, Peter Sallstig, et al.. (2017). Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 124(9). 1296–1304. 179 indexed citations

Dugel, Pravin U., James Warburton, Andreas Weichselberger, & Peter Sallstig. (2016). A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen. 57(12). 5018–5018. 4 indexed citations

Singerman, Lawrence J., Andreas Weichselberger, & Peter Sallstig. (2015). OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Investigative Ophthalmology & Visual Science. 56(7). 4801–4801. 7 indexed citations

Schlesinger, Naomi, Marc De Meulemeester, A. Pikhlak, et al.. (2011). Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Research & Therapy. 13(2). R53–R53. 109 indexed citations

Schlesinger, Naomi, Eduardo Mysler, Hsiao‐Yi Lin, et al.. (2011). Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Annals of the Rheumatic Diseases. 70(7). 1264–1271. 175 indexed citations

Meulemeester, Marc De, A. Pikhlak, Eftal Yücel, et al.. (2011). Metabolic and crystal arthropathies: 112. Rapid Improvement in Health-Related Quality of Life in Gouty Arthritis Patients Treated with Canakinumab (ACZ885) Compared to Triamcinolone Acetonide. Lara D. Veeken. 50(Supplement 3). iii85–iii86. 3 indexed citations

Schnitzer, Thomas J., B. Seriolo, Hartmut Schneider, et al.. (2011). A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clinical Rheumatology. 30(11). 1433–1446. 11 indexed citations

Schlesinger, Naomi, Eduardo Mysler, Jozef Rovenský, et al.. (2011). Canakinumab Reduces The Risk Of Acute Gouty Arthritis Flares During Initiation Of Allopurinol Therapy: Results Of A Double-blind, Randomised Study. Journal of Allergy and Clinical Immunology. 127(2). AB227–AB227. 7 indexed citations

So, Alexander, Eftal Yücel, Udayasankar Arulmani, et al.. (2011). Canakinumab Relieves Symptoms of Acute Flares and Improves Health-Related Quality Of Life (HRQoL) in Difficult-To-Treat Gouty Arthritis Patients by Suppressing Inflammation: Results of a Randomized, Dose-Ranging Study. Journal of Allergy and Clinical Immunology. 127(2). AB227–AB227. 1 indexed citations

10.

So, Alexander, A. Pikhlak, Udayasankar Arulmani, et al.. (2010). Canakinumab (ACZ885) vs triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to nsaids and/or colchicine.. IRIS. 4 indexed citations

11.

So, Alexander, Marc De Meulemeester, A. Pikhlak, et al.. (2010). Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study. Arthritis & Rheumatism. 62(10). 3064–3076. 226 indexed citations

12.

Farkouh, Michael E., Freek W.A. Verheugt, Sean Ruland, et al.. (2008). A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen. Journal of Clinical Hypertension. 10(8). 592–602. 5 indexed citations

13.

Fleischmann, Roy, H Tannenbaum, Neha Patel, et al.. (2008). Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis. BMC Musculoskeletal Disorders. 9(1). 32–32. 17 indexed citations

14.

Hawkey, Christopher J., Wilfred M. Weinstein, Walter Smalley, et al.. (2007). Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology. 133(1). 57–64. 17 indexed citations

15.

Whitehead, Anne, Mark Simmonds, B. Mellein, et al.. (2006). P309 BLOOD PRESSURE PROFILE OF LUMIRACOXIB IS SIMILAR TO PLACEBO IN ARTHRITIS PATIENTS. Osteoarthritis and Cartilage. 14. S168–S169. 5 indexed citations

16.

Fleischmann, R., et al.. (2006). P302 RETENTION ON TREATMENT WITH LUMIRACOXIB IN PATIENTS WITH OSTEOARTHRITIS. Osteoarthritis and Cartilage. 14. S165–S165. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact